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Mutations in KAT6B, Encoding a Histone
Acetyltransferase, Cause Genitopatellar Syndrome
Philippe M. Campeau,1,17 Jaeseung C. Kim,2,17 James T. Lu,3,4 Jeremy A. Schwartzentruber,5
Omar A. Abdul-Rahman,6 Silke Schlaubitz,1 David M. Murdock,3 Ming-Ming Jiang,1 Edward J. Lammer,7
Gregory M. Enns,8 William J. Rhead,9 Jon Rowland,10 Stephen P. Robertson,11 Vale´rie Cormier-Daire,12
Matthew N. Bainbridge,3,4 Xiang-Jiao Yang,13,14 Marie-Claude Gingras,1,3 Richard A. Gibbs,1,3
David S. Rosenblatt,2,14,15 Jacek Majewski,2,5 and Brendan H. Lee1,16,*
Genitopatellar syndrome (GPS) is a skeletal dysplasia with cerebral and genital anomalies for which the molecular basis has not yet been
determined. By exome sequencing, we found de novo heterozygous truncating mutations in KAT6B (lysine acetyltransferase 6B,
formerly known as MYST4 and MORF) in three subjects; then by Sanger sequencing of KAT6B, we found similar mutations in three
additional subjects. The mutant transcripts do not undergo nonsense-mediated decay in cells from subjects with GPS. In addition,
human pathological analyses and mouse expression studies point to systemic roles of KAT6B in controlling organismal growth and
development. Myst4 (the mouse orthologous gene) is expressed in mouse tissues corresponding to those affected by GPS. Phenotypic
differences and similarities between GPS, the Say-Barber-Biesecker variant of Ohdo syndrome (caused by different mutations of
KAT6B), and Rubinstein-Taybi syndrome (caused by mutations in other histone acetyltransferases) are discussed. Together, the data
support an epigenetic dysregulation of the limb, brain, and genital developmental programs.Genitopatellar syndrome (GPS) [MIM 606170] is a rare
skeletal dysplasia combining hypoplastic or absent
patellae, genital anomalies, craniofacial defects, and intel-
lectual disability among other features. It has been
described in 18 subjects to date.1–11 In one patient, we
discovered a microdeletion encompassing LMX1B (ex-
plaining the patellar anomalies) and NR5A1 (explaining
the genital anomalies) though this was not found to be
a recurrent molecular lesion in the other subjects.11 An
important phenotypic difference is that the subject with
the microdeletion is not microcephalic although all other
subjects are.
To gain insights into the molecular cause of GPS, we re-
cruited subjects with this disease (see Figure 1 for photos,
Figure S1 [available online] for pedigrees, and Table 1 and
references therein for clinical details). Families provided
informed consent to our study approved by the institu-
tional review board of the Baylor College of Medicine.
Subject 3 died at 8 years of age from bowel malrotation
that led to volvulus and intestinal necrosis. An autopsy
showed dramatic pancreatic hyperplasia (103 g for an ex-
pected weight of 15 g) with hyperplasia of some of the
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282 The American Journal of Human Genetics 90, 282–289, Februarybeen described in other subjects, even though all other
subjects in this study had abdominal ultrasounds. Other
significant findings included kidney hypoplasia with
multiple small subcapsullar cysts, a prominent suprapubic
fat pad with underdeveloped clitoris and labia minora, and
an anteriorly placed anus. Skeletal features included flat
temporal bones, brachydactyly, flexion deformities of the
hips and knees, and markedly hypoplastic patellae. Neuro-
pathology showed microcephaly (851 g for an expected
weight of 1,273 g); mild to moderate diffuse cortical
atrophy; hypoplasia of the anterior portion of the corpus
callosum; generalized mild gliosis; and small perivascular
psammomatous calcifications in the basal ganglia, thal-
amus, corpus callosum, choroid plexus, and periventricu-
lar regions. See Figures 2A–2D for histology of some
relevant tissues. Psammoma bodies are calcifications
frequently seen in meningiomas and other malignancies
(and only rarely in benign overgrowths) and are thought
to result from calcification of dead cells or an active process
to inhibit cell growth.12
We performed whole-exome sequencing on three
subjects (subjects 2, 4, and 5). For subjects 2 and 4,
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Figure 1. Clinical Presentation of Subjects with GPS
Photographs of (A) subject 2 at 9 years of age, (B) subject 3 at 8
years of age, and (C) subject 5 at birth and at 8 months of age.library and sequencing was conducted on Illumina Hi-
Seq. Sequences were aligned to the human reference
genome (hg18) with Burrows-Wheeler Aligner (BWA) (v
0.5.9)13 and recalibrated with the Genome Analysis Tool-
kit (GATK). Both samples achieved over 91% targeted
bases at 203 coverage. SNPs and insertion-deletion
events were called with Samtools Pileup (version
0.1.17).14 Variants were annotated with ANNOVAR15
and protein-impacting variants that were rare (minor
allele frequency < 5%), novel, and nonsynonymous
were preferentially explored. We narrowed gene candi-
dates by comparing with known functional databases
such as dbNSFP16 and SWISS-PROT17 to narrow down
the list of plausible causative variants. For subject 5, the
exome was captured on the Agilent SureSelect 50 Mb
oligonucleotide library. DNA was sheared by sonication
to an approximately 200 bp length. Fragment ends
were ligated to specific adaptors and capture was per-
formed with the manufacturer’s protocol. The captured
exome was reamplified by PCR (12 cycles) then applied
to a single lane of Illumina HiSeq sequencer. The Illu-
mina reads were aligned to the reference human genome
(hg19) with BWA (v. 0.5.9) and Samtools (v. 0.1.12a).
Pileup and varFilter commands were used to call variants,
and these were filtered to retain SNPs and insertion-dele-
tions with Phred-like quality scores of at least 20 and 50,
respectively. ANNOVAR was used to annotate nonsynon-
ymous variants according to the type of mutation, occur-
rence in dbSNP, SIFT score,18 and 1000 Genomes allele
frequency.19
As shown in Table 2, only 13 genes showed rare novel
variants that were potentially pathogenic and were sharedThe Americaby the three subjects. Variants were visualized and
compared to the exomes of 20 other subjects with unre-
lated conditions. When keeping only high-quality vari-
ants (e.g., removing probable false positive variants in
repeat regions or variants seen in unrelated conditions),
only KAT6B variants remained. All variants were frame-
shift insertions-deletions (Figure 3, Figures S2A–2C, avail-
able online, and Table 3; RefSeq NM_012330.2 was used
for the positions). We confirmed the variants by Sanger
sequencing and sequenced the complete coding sequence
of the gene in the other individuals recruited in our study
(see Table S1 for primers). We have thus identified
nonsense mutations in two additional subjects and one
of the previously identified frameshift deletions in another
(Figure 3 and Figures S2D–2F). Analysis of parental
samples from five subjects showed that the mutations
were acquired de novo (Figure S2). All mutations lead to
a loss of the highly conserved transcription activation
domain (Figure 3 and Figure S3). The Exome Variant Server
has public information on KAT6B for over 1,100 individ-
uals of European descent and 900 African Americans,
with an average coverage of over 853 for the coding
sequences of KAT6B. No truncating mutations of KAT6B
were identified in this server or in other exomes performed
by Baylor College of Medicine’s Human Genome
Sequencing Center.
Lymphoblastoid cells were established by Epstein-Barr
virus infection for subjects 1 through 4. One million cells
were collected, and RNA was extracted with Trizol, treated
with DNase I, then phenol-chloroform extracted. The
first strand of cDNA was synthesized with oligo dT
primers via Invitrogen’s SuperScript III First-Strand
synthesis kit. For RT-PCR, a 50 nuclease assay from Inte-
grated DNA Technologies (Coralville, IA) was designed
with probes having a 50 fluorescein amidite fluorophore,
a 30 IBFQ quencher, and an internal ZEN quencher (see
Table S1). Quantitative real-time PCR was performed in
an ABI 7900 HT machine with ABI’s TaqMan Universal
PCR Master Mix according to the manufacturer’s instruc-
tions (Figure 4A). We also amplified cDNA by using
primers encompassing the last exon-exon junction and
the most 50 mutations and sequenced the products (see
Table S1 for primers). These experiments demonstrate
that the mutant mRNAs do not undergo nonsense-
mediated decay (Figures 4A and 4B), which is consistent
with localization of the premature stop codons in the
last exon. To assess the expression pattern of Myst4
in organs known to be affected by GPS, we performed
immunohistochemistry on mice of various develop-
mental ages. The primary antibody used is Sigma
AV38985 (1:200 dilution), the secondary is Invitrogen
A-11012 (1:600 dilution). The specificity of the antibody
for the mouse protein was confirmed by showing a
staining pattern in the brain compatible with published
RNA in situ experiments20 (see Figure 5A). Myst4 is
strongly expressed in the telencephalic vesicles, trigem-
inal ganglion, spinal cord, dorsal root ganglia, digestiven Journal of Human Genetics 90, 282–289, February 10, 2012 283
Table 1. Clinical Features of Enrolled Subjects and 13 Other Subjects from the Literature
Subjects 1 2 3 4 5 6 Literaturea Total (Affected/Total)
Gender female male female male female male 4 females/9 males 7 females/12 males
Skeletalb
Absent or hypoplastic
patellae
þ þ þ þ þ þ 12 18/19
Flexion deformities þ þ þ þ þ þ 13 19/19
Club feet þ þ þ þ þ þ 12 18/19
Thoracolumbar kyphosis
or scoliosis
þ þ 3 5/19
Pelvic anomalies þ þ 5 7/19
Costal anomalies þ þ þ 1 4/19
Neurologicalc
Microcephaly þ þ þ þ þ þ 13 19/19
Developmental delay or
intellectual disability
þ þ þ þ þ þ 10/10d 16/16
Absent or thin corpus
callosum
þ þ þ þ þ þ 9 15/19
Colpocephaly or
ventriculomegaly
þ þ þ 1 4/19
Pachygyria þ 2 3/19
Subependymal
periventricular
nodular heterotopia
þ 1 2/19
Optic atrophy
or cortical visual
impairment
þ þ þ 0 3/19
Hearing loss þ þ 1 3/19
Anal and Genitale
Anteriorly positioned anus þ þ 1 3/19
Anal atresia or stenosis þ þ 0 2/19
Hypoplastic labia minora
or majora
þ þ þ 3 6/6
Clitoromegaly þ þ 3 5/6
Scrotal hypoplasia þ þ þ 9 12/12
Cryptochidism þ þ þ 9 12/12
Renalf
Hydronephrosis þ þ þ þ 11 16/19
Multicystic kidneys þ þ 4 6/19
Cardiacg
Atrial septal defect þ þ þ þ 3 7/19
Ventricular septal defect þ 3 4/19
Facialh
Facial dysmorphisms þ þ þ þ þ þ 13 19/19
Broad nasal bridge þ þ 7 9/19
Prominent nasal bridge þ þ 3 5/19
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Table 1. Continued
Subjects 1 2 3 4 5 6 Literaturea Total (Affected/Total)
Otheri
Tracheo or laryngomalacia þ þ 4 6/19
Feeding difficulties þ þ þ þ 2 6/19
Small bowel malrotation þ 1 2/19
Hypothyroidism þ 2 3/19
a From Armstrong and Clarke,2 Bergmann et al.,3 Brugha et al.,4 Cormier-Daire et al.,5 Goldblatt et al.,6 Penttinen et al.,9 and Reardon10.
b Occasional findings include osteoporosis, radioulnar synostosis, radial head deformity, brachydactyly, short stature, joint laxity, dislocated patellae, undertubu-
lation of long bones, coxa vara, camptodactyly, narrow thorax, and exostoses.
c Occasional findings include hypotonia, hypertonia, seizures, and subdural hemorrhage (subject 5).
d Ten out of thirteen children survived beyond neonatal period and were included.
e Occasional findings include rectal duplication (subject 6) and underdeveloped clitoris (subject 3).
f Occasional findings include fused renal ectopia, dysplastic kidneys, and hypoplastic kidneys (subject 3).
g Occasional findings include tortuous ascending aorta, dilated aortic arch, patent ductus arteriosus, patent foramen ovale, and stenosis of the pulmonary
valve.
h Occasional findings include bulbous nose, retrognatia or micrognatia, cleft or high-arched palate, gingival hyperplasia, coarse facies, full cheeks, ear anomalies,
dental anomalies, sparse hair, hypertelorism, plagiocephaly, bitemporal flattening, downslanting palpebral fissures, downturned corners of the mouth, short colu-
mella, short philtrum, tented upper lip, and midface hypoplasia.
i Occasional findings include hypogonadotrophic hypogonadism, respiratory distress, apnea, recurrent infections, single palmar crease, and skin laxity.tract, pancreas liver and ribs of developing embryos
(Figures 5A and 5B). After birth, it is strongly expressed
in the diaphysis of the long bones, the kidney, and the
patella, among other organs (Figures 5C–5K).
KAT6B has a highly conserved acetyltransferase
domain21 and has been shown to fuse with p300 and
CBP following chromosomal translocations in acute
myeloid leukemia and myelodysplastic syndrome.22Figure 2. Hematoxylin and Eosin Images of Tissues from the
Autopsy of Subject 3
Tissues shown are (A) the brain (4003) where we show a large
cluster of perivascular calcifications in the white matter of the
cerebral cortex (arrows point to two of them); these are never
present in normal tissue; (B) the pancreas (1003) showing
numerous islets of Langerhans, some of which are hyperplastic
(black arrows), whereas others are of normal size (red arrows);
(C) the kidney (1003), where we show one large and one small
subcapsular cyst (arrows), and (D) the severely hypoplastic patella
(1003), where there is persistence of the cartilaginous core of the
trabeculae (black arrow).
The AmericaKAT6B has been reported to interact with the RUNX
family of transcription factors22 and form a tetrameric
complex with BRPFs, ING5, and EAF6.23,24 KAT6B was
pulled down in a PPAR-alpha interacting cofactor
complex,25 and a yeast two-hybrid screen identified
Atrophin-1 as a binding partner of KAT6B.26 Indepen-
dently to its cloning in humans, the mouse ortholog of
KAT6B was identified by screening a gene-trap library for
genes highly expressed in the telencephalon.20 Mice
carrying a hypomorphic mutation of Myst4 have short
stature, an absence of fusion of the tibia and fibula, micro-
cephaly with neurogenesis defects, early demise, and
infertility.27 A subject with a Noonan-like phenotype
has recently been identified to harbor a chromosomal
translocation disrupting KAT6B after exon 3, and the
mRNA levels in lymphoblastoid cells were half of
normal.28 Given the phenotypic difference between the
subject with a Noonan-like phenotype and subjects withTable 2. Number of Variants Identified
Subject 2 Subject 4 Subject 5
Shared
(2 of 3)
Shared
(3 of 3)
Total variants 2654026 2760221 490885
Total variants
after base
quality
filtering
1090174 1115186 256344
Novel variants
(dbSNP129/1000G)
872368 886839 237419
Genes with rare
nonsynonymous
variants, splice
site variants,
insertions or
deletions
variants in
coding regions.
440 367 273 76 13
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Figure 3. Location of Mutations Identified in KAT6B
The five different mutations form a cluster within the C-terminal acidic domain of KAT6B. The 16 coding exons and the corresponding
introns of KAT6B are depicted with boxes and solid lines, respectively, with introns not shown to scale. The encoding domains are
indicated below the exon-intron organization, along with the corresponding functions. The longest isoform is shown (isoform 1 in
uniprot, a.k.a. MORF-beta, CCDS7345, 2073 aa). The following abbreviations are used: H15, histone H1- or H5-like domain; PHD,
tandem plant homeodomain-linked zinc fingers. The amino acid changes resulting from five independent mutations present in 6
different subjects are indicated above the schematic exon-intronic structure. The mutations result in C-terminal truncation and re-
move the transcriptional activation domain, with the resulting mutant impaired in transcriptional activation. Deletions are shown
in black arrows, nonsense mutations in green, and the complex insertion-deletion mutation in red. Sequence details of the mutations
are shown in Table 3.GPS (Table 4), the persistent expression of a truncated
protein in GPS, containing intact N-terminal domain
and HAT domains but lacking the C-terminal transcrip-
tional activation domain, most likely leads to dominant-
negative or gain-of-function effects on cellular signaling.
Of relevance, leukemia-associated translocations also
generate similar KAT6B fragments fused to p300 and
CBP.22 Rubinstein-Taybi syndrome [MIM 180849] is
caused by de novo mutations inactivating the histone ace-
tyltransferase activity of the latter two enzymes, and both
haploinsufficiency and dominant-negative models have
been postulated for this condition.29,30 Although the
presentation is distinct from GPS, the two conditions
share some facial features, as well as intellectual disability,
malformations of the heart and kidneys, and unde-
scended testes. Recently, similar de novo truncating in
KAT6B mutations were identified in subjects with the
Say-Barber-Biesecker variant of Ohdo syndrome [MIM
249620], which overlaps with Genitopatellar syndrome
in terms of facial features and congenital heart
defects.31,32 The mutations are however usually located
more distally in the C terminus, specifically in the tran-
scriptional activation domain, and there are several clin-
ical differences: structural brain defects, skeletal defects,
anal anomalies, genital anomalies and renal defects areTable 3. Mutations Identified in the Subjects
Subject Mutation (DNA) Mutation (Protein)
1 c.3892G>T p.Gly1298*
2 c.4360_4368delinsAAAAACCAAAA p.Glu1454LysfsX8
3 c.3802G>T p.Gly1268*
4 c.3769_3772delTCTA p.Lys1258GlyfsX13
5 c.3788_3789delAA p.Lys1263ArgfsX7
6 c.3769_3772delTCTA p.Lys1258GlyfsX13
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palatal, and thyroid defects are more severe or frequent
in the Say-Barber-Biesecker variant of Ohdo syndrome. A
comparison of the phenotypes of GPS, the Say-Barber-Bie-
secker variant of Ohdo syndrome, the child with a translo-
cation involving KAT6B, and Rubinstein-Taybi syndrome
is shown in Table 4.
We have thus identified mutations in the epigenetic
regulator KAT6B in several subjects with GPS. Because
this acetyltransferase is a ubiquitous transcriptional coacti-
vator, searching for more binding partners and studying its
role in skeletogenesis and development in general might
lead to important insights into epigenetic dysregulation
in GPS and related diseases.
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Figure 4. Mutant Transcripts Do Not Undergo Nonsense-Mediated Decay
(A) Messenger RNA levels of KAT6B, normalized toGAPDH, in lymphoblastoid cell lines derived from subjects 1–4, and from control cell
lines (n ¼ 3) (data are represented as mean5 standard error of the mean).
(B) Sequencing of cDNA from those cells to demonstrate definitively that the mutant transcripts do not undergo nonsense-mediated
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Table 4. Phenotypic Differences between GPS, the Say-Barber-Biesecker Variant of Ohdo Syndrome, a Subject with a Translocation
Truncating KAT6B after Exon 3, and Rubinstein-Taybi Syndrome
Genitopatellar
Syndrome
Say-Barber-Biesecker
Variant of Ohdo
Syndrome
Subject with Noonan-Like
Phenotype and N-Terminal
Truncation of KAT6B Rubinstein Taybi Syndrome
Neurological
anomalies
DD/ID,a microcephaly in
all, agenesis of the corpus
callosum, colpocephaly
DD/ID, microcephaly
in minority, hypotonia,
no structural defects
microcephaly, ADHD,b
IQ 75-80, no structural
defects
DD/ID, seizures,
no structural defects
Facial anomalies broad or prominent nasal
bridge, bulbous nose in
minority, full cheeks
in minority
blepharophimosis, ptosis,
broad and flat nasal
bridge, bulbous nose, full
cheeks, abnormal ears, small
mouth, expressionless
or mask-like facies
blepharophimosis, ptosis,
arched eyebrows, abnormal
ears, smooth philtrum,
retrognatia, high-arched
palate
arched eyebrows, downslanting
palpebral fissures, beaked nose
with the columella extending
below the nares, high-arched
palate, mild micrognathia,
grimacing smile
Musculo-skeletal
anomalies
absent or hypoplastic
patellae in majority,
flexion contractures,
club feet, costo-vertebral
anomalies, pelvic anomalies
long thumbs and toes,
patellar anomalies
in minority
short stature, retarded
bone age, ligamentous
laxity
short stature, joint hypermobility,
broad thumbs and broad big toes
Anal and genital
anomalies
anal anomalies, hypoplastic
labia, clitoromegaly, scrotal
hypoplasia, cryptorchidism
cryptorchydism and
hypospadias
Heart anomalies congenital heart defects congenital heart defects congenital heart defects
Structural eye
defects
none frequent frequent
Dental anomalies rare frequent
Cleft palate rare frequent
Hearing
impairment
rare frequent
Thyroid
abnormalities
rare frequent
Renal anomalies hydronephrosis or cysts
in a majority
vesicoureteric reflux
in one individual
Other feeding difficulties,
tracheomalacia, respiratory
difficulties, small bowel
malrotation
feeding difficulties feeding difficulties, respiratory
difficulties, skin anomalies
(hirsutism, naevus flammeus
on the forehead, and
keloid formation), malignancies
a DD/ID is used as an abbreviation for developmental delay or intellectual disability.
b ADHD is used as an abbreviation for Attention deficit hyperactivity disorder.Received: September 27, 2011
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